Showing 1461-1470 of 2149 results for "".
- Straight Up: Paula Abdul Is InMode's New Brand Ambassadorhttps://practicaldermatology.com/news/straight-up-paula-abdul-is-inmodes-new-brand-ambassador/2460122/Paula Abdul is InMode’s new brand ambassador for BodyTite, FaceTite and Morpheus8 technologies. As a lifelong performer, Abdul has always taken care of herself and has the muscles to prove it—however, at age 57, she acknowledg
- Homemade Sunscreens Shared on Pinterest May Do More Harm than Goodhttps://practicaldermatology.com/news/homemade-sunscreens-shared-on-pinterest-may-do-more-harm-than-good/2460035/Nearly all—95 percent—of pins for homemade sunscreen found on Pinterest positively portrayed the effectiveness of the sunscreen and most—68 percent—recommended recipes for homemade sunscreens that offered insufficient UV protection, according to a
- AAD: Half of Americans Aren't Protecting Themselves from the Sunhttps://practicaldermatology.com/news/aad-half-of-americans-arent-protecting-themselves-from-the-sun/2460018/Most Americans aren’t using sun protection as often as they should be —increasing their risk for skin cancer, including melanoma. In fact, just half of Americans always or almost always protect themselves from the sun when they’re outside, according to a new survey by
- Galderma Collaborates with Nespresso to Offer Patient Loyalty Incentive Programhttps://practicaldermatology.com/news/galderma-collaborates-with-nespresso-to-offer-patient-loyalty-incentive-program/2459968/Galderma Laboratories, L.P., recently teamed up with Nespresso to offer a new rewards program for patients who seek Restylane treatments from aesthetic professionals. With a qualifying purchase of Restylane dermal fillers, aesthetic professionals will receive a set of vouchers for complimentary N
- New Mouse Model Validates How “Good” and “Bad” Bacteria Affect Acnehttps://practicaldermatology.com/news/new-mouse-model-validates-how-good-and-bad-bacteria-affect-acne/2459981/Researchers at University of California San Diego School of Medicine, Cedars-Sinai and UCLA have developed a new mouse model that closely resembles human acne by adding one new factor — a synthetic sebum. Researchers have long believed that Propionibacterium acnes causes ac
- Key West Bans Sunscreens with Oxybenzone and Octinoxatehttps://practicaldermatology.com/news/key-west-bans-sunscreens-with-oxybenzone-and-octinoxate/2459911/Following Hawaii’s lead, Florida’s Key West City Commission voted to ban the sale of products that contain oxybenzone or octinoxate — two chemicals in sunscreen that have been shown to wash off and potentially damage coral reefs. The ban takes effect in January 2021. Fir
- Galderma Forms Women In Aesthetics Leadership Councilhttps://practicaldermatology.com/news/galderma-forms-women-in-aesthetics-council/2459928/Galderma Laboratories, L.P. has formed a Women in Aesthetics Leadership Council, comprised of clinicians, clinical trial investigators, CEOs, business owners, and practice managers. "In most industries in the US women hold just 25 percent of senior leadership positions
- Milestone Alert: Galderma's ASPIRE Rewards Program Hits the Million Member Markhttps://practicaldermatology.com/news/milestone-alert-galdermas-aspire-rewards-program-hits-the-million-member-mark/2457530/Galderma Laboratories, L.P’s ASPIRE Rewards program has reached the one million member milestone. ASPIRE is a loyalty program for consumers and aesthetic providers who use Galderma aesthetic injectab
- Opdivo Plus Yervoy Demonstrates Durable Four-Year Survival Benefits in Advanced Melanomahttps://practicaldermatology.com/news/opdivo-plus-yervoy-demonstrates-durable-four-year-survival-benefits-in-advanced-melanoma/2457552/Four-year data from the Phase 3 CheckMate-067 clinical trial—the longest follow-up to date—continue to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in
- Galderma Ups Its Aesthetic R&D Gamehttps://practicaldermatology.com/news/galderma-ups-their-aesthetic-r-d-game/2457570/Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials. The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology products; two studies for Dysport evaluating patient satisfaction and